Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) received a $3.00 target price from analysts at B. Riley in a research note issued to investors on Friday, February 16th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. B. Riley’s price objective suggests a potential upside of 435.71% from the stock’s current price.
Other equities analysts have also recently issued research reports about the company. Maxim Group reissued a “buy” rating and issued a $3.00 price target on shares of Actinium Pharmaceuticals in a research note on Wednesday, October 25th. Zacks Investment Research cut Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Finally, Roth Capital reissued a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $3.75.
Shares of Actinium Pharmaceuticals (ATNM) opened at $0.56 on Friday. Actinium Pharmaceuticals has a 1 year low of $0.53 and a 1 year high of $1.68. The company has a market cap of $45.61, a PE ratio of -1.19 and a beta of 40.77.
An institutional investor recently raised its position in Actinium Pharmaceuticals stock. D.A. Davidson & CO. grew its position in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 157,000 shares of the biotechnology company’s stock after buying an additional 109,000 shares during the quarter. D.A. Davidson & CO. owned approximately 0.20% of Actinium Pharmaceuticals worth $104,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/23/b-riley-analysts-give-actinium-pharmaceuticals-atnm-a-3-00-price-target.html.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.